HWGB Biotech enters COVID-19 vaccine R&D agreements

KUALA LUMPUR (BERNAMA) – HWGB Biotech Sdn Bhd’s joint venture partner, United States (US)-based E-MO Biology Inc (EBI), entered into three research and development (R&D) agreements to produce COVID-19 vaccines.

EBI’s contracts are with Dr John Andrews through Black Diamond Networks (professional service agreement), Roderick A Comunale II MD Inc, and America Diagnostic and Genescan Diagnostics Inc.

HWGB Biotech Chief Executive Officer Datuk Aaron Lim said the agreements would bring in expertise that will help boost clinical trials in accordance with US laws.

“We look forward to the fruitful work that will come from the collaborations with our partners.

“Time is important in the production of the vaccine given how the pandemic ravaged Southeast Asia’s population and its economies,” he said in a statement.

HWGB Biotech is a wholly owned subsidiary of Ho Wah Genting Bhd while EBI, incorporated in California, US is principally involved in conducting biology R&D and is the sponsor of a study which indicates booster polio vaccine to reduce COVID-19 SARS-COV-2 infection and severity.